BIOC   $0.4299  -14.87% Market Closed

Biocept Inc
Last Events:

2023-08-09 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-05 Signal in Stochastic changed from bearish weakening to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: exit from the oversold zone.

2023-08-05 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-04 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-04 Signal in MACD changed from bearish recovery to bearish weakening. Oscillator MACD is in the negative territory it's higher than the signal line and grows. These factors mean that the falling period is over. Last signal: main and signal line crossing.

2023-08-03 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.


Current temperature: 1.81
ST: 0, Cor:

Analyst Recommendations:
Number of estimates
Target Price Mean
Mean unverified/preliminary /
Target Price Low / High /
Median / STD DEV /
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None Sell None
rsi Buy Sell ActivelyBuy
macd None None None
stoch None None None
ma20 Sell Sell ActivelyBuy
ma50 None None None
ma100 None None Sell
Candlestick PatternOct. 23, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US09072V6002
ceo Mr. Antonino Morales
Website https://biocept.com
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.